You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RNAi

Showing 1 - 25 of 71
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PH1, Primary Hyperoxaluria, RNAi Therapeutic Trial in Worldwide (Lumasiran)

Active, not recruiting
  • PH1
  • +4 more
  • Bordeaux, France
  • +8 more
Jan 13, 2023

Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin Trial in Marlborough (PH-762)

Not yet recruiting
  • Squamous Cell Carcinoma of the Skin
  • +2 more
  • Marlborough, Massachusetts
    Phio Pharmaceuticals Corp.
Aug 25, 2023

Familial Chylomicronemia Syndrome Trial (VSA001 injection, Placebo)

Not yet recruiting
  • Familial Chylomicronemia Syndrome
  • VSA001 injection
  • Placebo
  • (no location specified)
Jun 9, 2023

Healthy Adult Volunteers Trial in Beijing (VSA001 injection, Placebo)

Not yet recruiting
  • Healthy Adult Volunteers
  • VSA001 injection
  • Placebo
  • Beijing, Beijing, China
    Peking University Third Hospital
Feb 23, 2023

Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy Trial (Patisiran)

Available
  • Transthyretin-mediated Amyloidosis With Cardiomyopathy
  • ATTR Amyloidosis With Cardiomyopathy
  • (no location specified)
Aug 17, 2022

Pathogenesis of Hematologic Malignancies

Enrolling by invitation
  • Acute Leukemia
  • +3 more
  • blood draw, bone marrow procedure, or tissue biopsy
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 9, 2022

STARD3 in Colorectal Cancer: The STAR Study

Recruiting
  • Colorectal Cancer
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
    Nov 16, 2023

    Nonalcoholic Steatohepatitis, NASH Trial in Worldwide (ALN-HSD, Placebo)

    Active, not recruiting
    • Nonalcoholic Steatohepatitis
    • NASH
    • Huntington Park, California
    • +20 more
    Aug 11, 2022

    Hepatitis B, Chronic Trial in Worldwide (DCR-HBVS, Placebo for DCR-HBVS)

    Completed
    • Hepatitis B, Chronic
    • Clayton, Victoria, Australia
    • +8 more
    Sep 28, 2022

    Hemophilia A, Hemophilia B Trial in Worldwide (Fitusiran (SAR439774))

    Active, not recruiting
    • Hemophilia A
    • Hemophilia B
    • Fitusiran (SAR439774)
    • Ann Arbor, Michigan
    • +11 more
    Aug 4, 2022

    Amyloidosis Trial in Worldwide (Patisiran (ALN-TTR02))

    Completed
    • Amyloidosis
    • Patisiran (ALN-TTR02)
    • La Mesa, California
    • +55 more
    Jan 19, 2023

    Acute Intermittent Porphyria Trial in Sweden, United Kingdom, United States (givosiran (ALN-AS1))

    Completed
    • Acute Intermittent Porphyria
    • givosiran (ALN-AS1)
    • San Francisco, California
    • +4 more
    Nov 9, 2021

    Study of Transthyretin-Mediated Amyloidosis

    Recruiting
    • Transthyretin-Mediated Amyloidosis
    • ATTR Amyloidosis
      • La Jolla, California
      • +23 more
      Jan 13, 2023

      Primary Hyperoxaluria Type 3 Trial in Worldwide (DCR-PHXC, Sterile Normal Saline (0.9% NaCl))

      Completed
      • Primary Hyperoxaluria Type 3
      • Boston, Massachusetts
      • +5 more
      Sep 9, 2021

      Patisiran in Polyneuropathy of ATTRv Amyloidosis WithV122I or

      Active, not recruiting
      • Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
      • Polyneuropathy
      • Los Angeles, California
      • +26 more
      Mar 4, 2022

      Amyloid Neuropathies, Transthyretin Amyloidosis Trial in Marseille (Electrophysiological biomarkers, MRI biomarkers)

      Completed
      • Amyloid Neuropathies
      • Transthyretin Amyloidosis
      • Electrophysiological biomarkers
      • MRI biomarkers
      • Marseille, Paca, France
        Assistance Publique Des Hopitaux de Marseille
      Oct 2, 2022

      Normal Physiology Trial run by the NIAID (Methylprednisolone sodium succinate(Solu-Medrol), Topical methylprednisolone (Advantan

      Completed
      • Normal Physiology
      • Methylprednisolone sodium succinate(Solu-Medrol)
      • Topical methylprednisolone (Advantan emulsion 0 /1%)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Nov 18, 2022

      Alcohol Use Disorder (AUD) Trial in Glendale (DCR-AUD, Placebo for DCR-AUD)

      Active, not recruiting
      • Alcohol Use Disorder (AUD)
      • Glendale, California
        Parexel Los Angeles Early Phase Clinical Unit
      Sep 15, 2022

      Idiopathic Pulmonary Fibrosis Trial in Adelaide (SRN-001, Placebo)

      Not yet recruiting
      • Idiopathic Pulmonary Fibrosis
      • Adelaide, South Australia, Australia
        CMAX Clinical Research
      Aug 2, 2023

      Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, JNJ-64300535, ETV monohydrate)

      Active, not recruiting
      • Hepatitis B, Chronic
      • Edegem, Belgium
      • +12 more
      Jan 17, 2023

      Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil)

      Terminated
      • Hepatitis B, Chronic
      • Hillsborough, New Jersey
      • +11 more
      Dec 28, 2022

      Metabolic Syndrome, Protection Against Trial in Castellana Grotte (Table Grape supplement)

      Active, not recruiting
      • Metabolic Syndrome, Protection Against
      • Table Grape supplement
      • Castellana Grotte, Bari, Italy
        IRCCS Saverio de Bellis
      Mar 20, 2022

      Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Israel, United States (siG12D-LODER, Gemcitabine+nab-Paclitaxel,

      Recruiting
      • Pancreatic Ductal Adenocarcinoma
      • Pancreatic Cancer
      • Hackensack, New Jersey
      • +8 more
      Jun 30, 2021

      Cardiac Amyloidosis : Diagnostic Using Red Flag Signals

      Recruiting
      • Cardiac Amyloidosis
      • diagnostic algorithm
      • Basse-Terre, Guadeloupe
      • +2 more
      Nov 16, 2020

      Cystinosis, Primary Hyperoxaluria Trial in Hanover (Diagnostic test)

      Recruiting
      • Cystinosis
      • Primary Hyperoxaluria
      • Diagnostic test
      • Hanover, Lower Saxony, Germany
        Screening Laboratory Hanover
      Apr 24, 2023